Search clinical trials for: Lumigan

Total 72 results

Amneal Pharmaceuticals, LLC
CBCC Global Inc.; Amneal EU, Limited

Not yet recruiting

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Ocular Hypertension | Open-angle Glaucoma

United States
Amneal Pharmaceuticals, LLC
CBCC Global Research

Recruiting

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Ocular Hypertension | Glaucoma, Open-Angle

United States
Salus University

Not yet recruiting

Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma (NTG)

Normal Tension Glaucoma

United States
AbbVie

Recruiting

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States, Japan
Laboratoires Thea

Completed

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Ocular Hypertension | Glaucoma

United States, Colombia
Laboratoires Thea

Completed

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

Ocular Hypertension | Glaucoma

Estonia
University of Miami
National Eye Institute (NEI)

Active, not recruiting

Stop Retinal Ganglion Cell Dysfunction Study (STOP-RGCD)

Glaucoma

United States
Laboratoires Thea

Completed

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Healthy Volunteers

United States
AbbVie

Completed

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Mankind Pharma Limited
CBCC Global Research

Completed

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma (Glaucoma)

Glaucoma, Open-Angle

United States
Sun Pharmaceutical Industries Limited

Withdrawn

A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open Angle Glaucoma
National Taiwan University Hospital

Unknown

Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study

Glaucoma; Ocular Disorders (I.E. Caused by Ocular Disorders)

Taiwan
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US (XLT)

Ocular Hypertension | Glaucoma

United States
Laboratoires Thea

Completed

Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose

Primary Open Angle Glaucoma | Ocular Hypertension

France
Allergan

Completed

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States, Israel, Canada, Singapore, Philippines, Spain, Australia, Belgium, Brazil, Germany
Northwestern University
Allergan

Completed

Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure

Intraocular Pressure | Nail Growth Cessation

United States
University of California, San Diego

Completed

The Effects of the Water Drinking Test on Intraocular Pressure

Glaucoma

United States
Manistee Partners

Unknown

Topical Bimatoprost in the Treatment of Migraine

Migraine Disorders | Headache Disorders

United States
Allergan

Completed

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

Ocular Hypertension | Open Angle Glaucoma

United States
Allergan

Completed

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons

Ocular Hypertension | Glaucoma, Primary Open Angle

Germany
Allergan

Completed

A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension (LOTUS)

Ocular Hypertension | Glaucoma, Open-Angle

China
Allergan

Completed

Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

China
Allergan

Completed

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
ForSight Vision5, Inc.

Completed

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert (OLE2)

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
ForSight Vision5, Inc.

Completed

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Alcon Research

Completed

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

Ocular Hypertension | Open-Angle Glaucoma

United States
Allergan

Completed

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
Rabin Medical Center

Completed

Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues

Thyroid Associated Ophthalmopathies

Israel
Credit Valley EyeCare
Canadian Glaucoma Clinical Research Council

Unknown

Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves

Glaucoma

Canada
Universitaire Ziekenhuizen KU Leuven
Allergan

Unknown

Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml (SPORTII)

Ocular Hypertension | Glaucoma

Belgium, Austria, Italy, Switzerland, United Kingdom
Cardiff University
National Institute for Social Care and Health Research

Completed

Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) (BIMA)

Graves' Ophthalmopathy

United Kingdom
Summa Health System

Completed

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Glaucoma | Application Site Pigmentation Changes

United States
Allergan

Completed

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Canada
Allergan

Completed

A Study of Bimatoprost 0.01% in the Clinical Setting (APPEAL-Taiwan)

Ocular Hypertension | Glaucoma, Primary Open Angle

Taiwan
Alcon Research

Completed

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

Ocular Hypertension | Glaucoma
Alcon Research

Completed

Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue

Ocular Hypertension | Open Angle Glaucoma
Allergan

Completed

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction

Ocular Hypertension | Glaucoma, Open-Angle

Canada
Allergan

Completed

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Allergan

Completed

A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension (LOTUSDI)

Ocular Hypertension | Glaucoma, Open-Angle

China
Duke University

Completed

Study of Bimatoprost Gel on Eyelash Growth

Hypotrichosis | Madarosis

United States
University of California, San Diego

Completed

24-hour IOP-lowering Effect of 0.01% Bimatoprost

Ocular Hypertension | Glaucoma | Intraocular Pressure

United States
Allergan

Completed

A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Germany, Netherlands
Allergan

Completed

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Glaucoma, Open-Angle

Austria
University of Miami

Completed

Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes

Hypertrichosis

United States
Allergan

Completed

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Switzerland

3

Subscribe